Rib-X Pharmaceuticals, a New Haven, CT-based developer of antibiotics, announced that its antibiotic delafloxacin in both 300 mg and 450 mg doses was as effective as an FDA-approved antibiotic in treating patients with complicated skin and skin structure infections in a mid-stage clinical trial. In October I wrote a feature profile about Rib-X and its next-generation antibiotics for treating antibiotic-resistant infections caused by MRSA and other lethal bacteria.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
